Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

DNLI

Denali Therapeutics Inc

May 03 • 04:00PM ET

17.14

Dollar change +0.33
Percentage change 1.96	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB IWM VXF VBK IWO IBB SCHA VTWO VHT

Index	RUT	P/E	-	EPS (ttm)	-1.09	Insider Own	19.30%	Shs Outstand	138.39M	Perf Week	11.08%
Market Cap	2.44B	Forward P/E	-	EPS next Y	-2.53	Insider Trans	-0.70%	Shs Float	115.02M	Perf Month	-9.74%
Income	-145.22M	PEG	-	EPS next Q	-0.69	Inst Own	76.19%	Short Float	8.33%	Perf Quarter	6.79%
Sales	330.53M	P/S	7.39	EPS this Y	-143.61%	Inst Trans	-0.74%	Short Ratio	7.65	Perf Half Y	-9.93%
Book/sh	7.45	P/B	2.30	EPS next Y	2.18%	ROA	-11.11%	Short Interest	9.58M	Perf Year	-33.72%
Cash/sh	7.26	P/C	2.36	EPS next 5Y	-	ROE	-14.01%	52W Range	14.56 - 33.31	Perf YTD	-20.13%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-21.99%	ROI	-13.50%	52W High	-48.54%	Beta	1.33
Dividend TTM	-	Quick Ratio	13.65	Sales past 5Y	264.19%	Gross Margin	95.49%	52W Low	17.72%	ATR (14)	0.89
Dividend Ex-Date	-	Current Ratio	13.65	EPS Y/Y TTM	59.36%	Oper. Margin	-59.51%	RSI (14)	48.85	Volatility	5.23% 4.62%
Employees	445	Debt/Eq	0.05	Sales Y/Y TTM	204.74%	Profit Margin	-43.94%	Recom	1.24	Target Price	40.27
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	-16.37%	Payout	-	Rel Volume	0.69	Prev Close	16.81
Sales Surprise	-100.00%	EPS Surprise	-6.97%	Sales Q/Q	-100.00%	Earnings	Feb 27 BMO	Avg Volume	1.25M	Price	17.14
SMA20	0.71%	SMA50	-9.16%	SMA200	-16.13%	Trades		Volume	868,033	Change	1.96%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-13-23	Initiated	Citigroup	Buy	$32
Nov-20-23	Resumed	JP Morgan	Overweight	$28
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$85 → $35
Sep-06-23	Initiated	B. Riley Securities	Buy	$38
Jan-30-23	Initiated	SVB Securities	Outperform	$50
Dec-05-22	Initiated	Cowen	Outperform
Nov-02-22	Upgrade	BTIG Research	Neutral → Buy	$38
Nov-02-22	Initiated	BofA Securities	Buy	$40
Jun-23-22	Initiated	Berenberg	Buy	$39
Dec-10-21	Resumed	Raymond James	Mkt Perform
Sep-21-21	Initiated	Oppenheimer	Outperform	$85
Sep-01-21	Initiated	SMBC Nikko	Outperform	$78
May-18-21	Initiated	UBS	Buy	$70
Feb-26-21	Reiterated	H.C. Wainwright	Buy	$80 → $95
Feb-10-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$105
Nov-11-20	Reiterated	H.C. Wainwright	Buy	$65 → $80
Oct-16-20	Downgrade	BTIG Research	Buy → Neutral
Sep-14-20	Resumed	JP Morgan	Overweight	$35
Aug-20-20	Reiterated	H.C. Wainwright	Buy	$28 → $45
Mar-13-20	Upgrade	Evercore ISI	In-line → Outperform	$20

Show Previous Ratings

May-01-24 08:00AM	Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial (GlobeNewswire)
Apr-09-24 08:46AM	Why Denali Therapeutics (DNLI) Stock Might be a Great Pick (Zacks)
Apr-08-24 08:00AM	Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences (PR Newswire)
Mar-28-24 11:30AM	Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report? (Zacks)
Mar-19-24 08:30AM	Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024 (PR Newswire)
08:08AM	Loading…
Feb-28-24 08:08AM	Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up (Zacks) -13.45%
Feb-27-24 08:31AM	Denali Therapeutics Inc (DNLI) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com) +38.25%
08:05AM	Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire)
08:00AM	Denali Therapeutics Announces $500 million Private Placement Equity Financing (GlobeNewswire)
06:53AM	Denali, fresh off study setback, gets $500M lift (BioPharma Dive)
Feb-16-24 08:39AM	UPDATE 2-Denali-Sanofi's ALS drug fails to meet mid-stage trial goal (Reuters) -7.30%
08:22AM	Denali-Sanofi's ALS drug fails to meet main goal of mid-stage trial (Reuters)
07:13AM	ALS drug from Denali, Sanofi falls short in mid-stage study (BioPharma Dive)
Feb-07-24 08:00AM	Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium (GlobeNewswire)
Feb-01-24 08:00AM	Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium (GlobeNewswire)
11:04PM	Loading…
Jan-31-24 11:04PM	Baillie Gifford Reduces Stake in Denali Therapeutics Inc (GuruFocus.com)
Jan-26-24 10:00AM	Denali's (DNLI) Pipeline Progresses Despite Stiff Competition (Zacks)
Jan-11-24 01:11PM	40 Cities with the Lowest Life Expectancy in the US (Insider Monkey)
Jan-09-24 08:44AM	DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING (PR Newswire)
Jan-08-24 08:00AM	Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases (GlobeNewswire) +5.27%
06:30AM	Flagship Pioneering Debuts Enabling Technologies Initiative (PR Newswire)
06:30AM	Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine (PR Newswire)
Jan-02-24 01:57PM	3 Biotech Stocks at the Forefront of the Quest for Eternal Youth (InvestorPlace)
Dec-22-23 06:22AM	40 Cities with the Highest Life Expectancy in the US (Insider Monkey)
Dec-21-23 09:55AM	Does Denali Therapeutics Inc. (DNLI) Have the Potential to Rally 123.38% as Wall Street Analysts Expect? (Zacks)
Dec-07-23 11:31AM	Why Is Denali Therapeutics Inc. (DNLI) Down 5.2% Since Last Earnings Report? (Zacks)
Nov-27-23 07:01PM	Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders (PR Newswire)
09:55AM	Wall Street Analysts See a 163.82% Upside in Denali Therapeutics Inc. (DNLI): Can the Stock Really Move This High? (Zacks)
Nov-21-23 06:00AM	Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics (PR Newswire) -5.11%
Nov-07-23 05:50PM	Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Loading…
04:01PM	Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Nov-06-23 09:55AM	Wall Street Analysts Think Denali Therapeutics Inc. (DNLI) Could Surge 121.53%: Read This Before Placing a Bet (Zacks)
Nov-01-23 10:30AM	Flagship Pioneering Launches Pioneering Intelligence (PR Newswire)
Oct-19-23 10:30AM	Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines (PR Newswire)
Oct-06-23 04:41AM	Orchard Therapeutics PLC Sponsored ADR (ORTX) Surges 96.0%: Is This an Indication of Further Gains? (Zacks)
Oct-02-23 07:00AM	Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics (PR Newswire)
Sep-27-23 08:31AM	Flagship Pioneering Named to Fortune's 2023 'Change the World' List (PR Newswire)
Sep-11-23 06:30AM	Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer (PR Newswire)
Sep-09-23 03:59PM	10 Biotech Stocks with Biggest Upside (Insider Monkey)
Sep-07-23 11:30AM	Why Is Denali Therapeutics Inc. (DNLI) Down 0.1% Since Last Earnings Report? (Zacks)
Aug-30-23 08:30AM	Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023 (GlobeNewswire)
Aug-29-23 09:00AM	Invaio achieves first registration for citrus greening solution featuring Trecise technology (PR Newswire)
Aug-11-23 11:36AM	20 Countries that Have the Most Billionaires Per Capita (Insider Monkey)
Aug-10-23 12:02PM	Denali (DNLI) Q2 Earnings Beat on Higher Collaboration Revenues (Zacks)
06:03AM	Pinning Down Denali Therapeutics Inc.'s (NASDAQ:DNLI) P/S Is Difficult Right Now (Simply Wall St.)
Aug-08-23 06:05PM	Denali Therapeutics Inc. (DNLI) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:01PM	Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Jun-29-23 05:13AM	Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now (InvestorPlace)
Jun-27-23 02:23PM	In the wake of Denali Therapeutics Inc.'s (NASDAQ:DNLI) latest US$402m market cap drop, institutional owners may be forced to take severe actions (Simply Wall St.)
Jun-26-23 10:00AM	Salt Lake City Ups the Ante in Bid to Become a Fintech Hub (The Wall Street Journal)
Jun-21-23 03:21PM	Denali (DNLI) Provides Update on Hunter Syndrome Study (Zacks)
06:00AM	Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs (PR Newswire)
Jun-20-23 04:20PM	Denali Says Hunter Syndrome Candidate Lowers Disease-Associated Biomarker (Benzinga)
07:00AM	Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome) (GlobeNewswire)
Jun-09-23 11:30AM	Why Is Amicus Therapeutics (FOLD) Up 8.1% Since Last Earnings Report? (Zacks)
Jun-08-23 11:30AM	Why Is Exelixis (EXEL) Down 0.6% Since Last Earnings Report? (Zacks)
Jun-07-23 11:30AM	Why Is Denali Therapeutics Inc. (DNLI) Up 11.9% Since Last Earnings Report? (Zacks)
Jun-05-23 06:15PM	Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure (Benzinga)
May-31-23 01:30PM	Denali Therapeutics (NASDAQ:DNLI) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
May-16-23 06:00AM	Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry (PR Newswire) -8.49%
May-15-23 04:31PM	Why Shares of Denali Therapeutics Are Up Monday (Motley Fool) +14.52%
May-09-23 01:24PM	Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus (Zacks)
May-08-23 05:15PM	Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
May-04-23 01:21PM	Is There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 40% Undervaluation? (Simply Wall St.)
May-01-23 10:00AM	Earnings Preview: Arcus Biosciences, Inc. (RCUS) Q1 Earnings Expected to Decline (Zacks)
Apr-27-23 10:02AM	Denali Therapeutics Inc. (DNLI) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-14-23 07:03AM	Denali Therapeutics' (NASDAQ:DNLI) investors will be pleased with their 28% return over the last five years (Simply Wall St.)
Apr-12-23 08:00AM	Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta (GlobeNewswire)
Apr-10-23 08:00AM	Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting (GlobeNewswire)
Apr-04-23 05:12AM	Y-mAbs Therapeutics, Inc. (YMAB) Surges 13.8%: Is This an Indication of Further Gains? (Zacks)
Mar-29-23 11:30AM	Why Is Denali Therapeutics Inc. (DNLI) Down 16% Since Last Earnings Report? (Zacks)
Mar-04-23 07:35AM	The Consensus EPS Estimates For Denali Therapeutics Inc. (NASDAQ:DNLI) Just Fell Dramatically (Simply Wall St.)
Feb-28-23 09:01AM	Denali (DNLI) Q4 Earnings Beat Estimates, Pipeline in Focus (Zacks)
Feb-27-23 05:35PM	Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Feb-23-23 11:15AM	Denali Therapeutics Reveals New Interim Data From Early-Stage Hunter Syndrome Study (Benzinga) -8.45%
Feb-22-23 04:33PM	Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium (GlobeNewswire)
Feb-21-23 10:00AM	Heska (HSKA) Earnings Expected to Grow: Should You Buy? (Zacks) -5.83%
Feb-20-23 10:00AM	Earnings Preview: Denali Therapeutics Inc. (DNLI) Q4 Earnings Expected to Decline (Zacks)
Feb-15-23 04:01PM	Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium (GlobeNewswire)
Feb-03-23 01:22PM	Denali Therapeutics Inc. (DNLI) Surges 5.8%: Is This an Indication of Further Gains? (Zacks)
Jan-25-23 08:00AM	Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi (GlobeNewswire)
Jan-09-23 08:00AM	Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases (GlobeNewswire)
Jan-02-23 06:56AM	With 63% ownership, Denali Therapeutics Inc. (NASDAQ:DNLI) boasts of strong institutional backing (Simply Wall St.)
Dec-13-22 08:15AM	Let's Take a Technical Peek at Denali Therapeutics (TheStreet.com) +5.40%
Dec-06-22 06:35AM	We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate (Simply Wall St.)
Dec-05-22 07:00AM	Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial (GlobeNewswire) -5.18%
Nov-09-22 05:32AM	Denali Therapeutics Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-04-22 11:52AM	Denali (DNLI) Lags Q3 Earnings Estimates, Pipeline in Focus (Zacks) -7.54%
06:23AM	Analysts' Revenue Estimates For Denali Therapeutics Inc. (NASDAQ:DNLI) Are Surging Higher (Simply Wall St.)
Nov-03-22 05:55PM	Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Nov-02-22 06:11PM	Why Denali Therapeutics' Stock Rose 6.6% on Wednesday (Motley Fool) +6.11%
Nov-01-22 08:00AM	Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN (GlobeNewswire)
Oct-24-22 04:30PM	Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Oct-19-22 09:19PM	Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock (GlobeNewswire) -15.06%
Oct-18-22 04:40PM	Denali Therapeutics Announces Proposed Offering of Common Stock (GlobeNewswire)
Oct-10-22 07:44AM	Investors in Denali Therapeutics (NASDAQ:DNLI) have made a decent return of 100% over the past three years (Simply Wall St.)
Oct-03-22 08:00AM	Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinsons Disease Associated with LRRK2 Pathogenic Mutations (GlobeNewswire)

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SATO VICKI L	Director	Apr 15 '24	Sale	18.29	1,666	30,471	118,043	Apr 17 05:14 PM
Krognes Steve E.	Director	Apr 01 '24	Sale	20.50	92,500	1,896,250	47,341	Apr 02 06:07 PM
SATO VICKI L	Director	Mar 15 '24	Sale	20.10	1,666	33,487	119,709	Mar 19 04:27 PM
SATO VICKI L	Director	Feb 15 '24	Sale	18.37	1,666	30,604	121,375	Feb 20 05:38 PM
Schuth Alexander O.	COFO and Secretary	Feb 14 '24	Sale	17.66	20,128	355,460	187,341	Feb 15 09:14 PM
Ho Carole	Chief Medical Officer	Feb 14 '24	Sale	17.79	1,405	24,995	143,605	Feb 15 09:14 PM
Watts Ryan J.	President and CEO	Feb 13 '24	Sale	17.29	9,589	165,794	238,067	Feb 15 09:15 PM
Ho Carole	Chief Medical Officer	Feb 13 '24	Sale	17.29	2,784	48,135	145,010	Feb 15 09:14 PM
Krognes Steve E.	Director	Feb 13 '24	Sale	17.29	2,750	47,548	139,841	Feb 15 09:16 PM
Schuth Alexander O.	COFO and Secretary	Feb 13 '24	Sale	17.29	2,716	46,960	207,469	Feb 15 09:14 PM
Schuth Alexander O.	COFO and Secretary	Feb 08 '24	Option Exercise	0.68	50,000	34,000	210,185	Feb 12 04:48 PM
SATO VICKI L	Director	Jan 16 '24	Sale	18.42	1,666	30,688	123,041	Jan 18 06:26 PM
Ho Carole	Chief Medical Officer	Jan 10 '24	Sale	19.02	4,668	88,785	147,794	Jan 12 08:18 PM
Watts Ryan J.	President and CEO	Jan 09 '24	Sale	19.78	7,818	154,640	2,268,363	Jan 11 05:28 PM
Watts Ryan J.	President and CEO	Jan 05 '24	Sale	19.43	17,483	339,695	2,276,181	Jan 09 07:33 PM
Ho Carole	Chief Medical Officer	Jan 05 '24	Sale	19.43	9,972	193,756	198,777	Jan 09 07:35 PM
Schuth Alexander O.	COFO and Secretary	Jan 05 '24	Sale	19.43	9,972	193,756	539,307	Jan 09 07:34 PM
Krognes Steve E.	Director	Jan 05 '24	Sale	19.43	3,208	62,331	142,591	Jan 09 07:34 PM
SATO VICKI L	Director	Dec 15 '23	Sale	23.39	1,666	38,968	124,707	Dec 18 07:30 PM
SATO VICKI L	Director	Nov 15 '23	Sale	19.13	1,666	31,871	126,373	Nov 16 06:14 PM
SATO VICKI L	Director	Oct 16 '23	Sale	20.66	1,666	34,420	128,039	Oct 18 04:44 PM
SATO VICKI L	Director	Sep 15 '23	Sale	23.62	1,666	39,348	129,705	Sep 19 04:45 PM
Ho Carole	Chief Medical Officer	Aug 23 '23	Sale	23.22	2,522	58,561	182,809	Aug 25 05:30 PM
Schuth Alexander O.	COFO and Secretary	Aug 23 '23	Sale	23.17	2,522	58,435	518,989	Aug 25 05:36 PM
Ho Carole	Chief Medical Officer	Aug 21 '23	Sale	22.60	2,478	56,003	185,331	Aug 23 04:34 PM
Schuth Alexander O.	COFO and Secretary	Aug 21 '23	Sale	22.59	2,478	55,978	521,511	Aug 23 04:33 PM
Watts Ryan J.	President and CEO	Aug 21 '23	Sale	22.59	2,309	52,160	2,242,604	Aug 23 04:32 PM
Krognes Steve E.	Director	Aug 21 '23	Sale	22.60	1,419	32,069	145,799	Aug 23 04:31 PM
SATO VICKI L	Director	Aug 15 '23	Sale	24.30	1,666	40,484	131,371	Aug 17 06:42 PM
Ho Carole	Chief Medical Officer	Aug 14 '23	Sale	23.79	2,768	65,851	182,809	Aug 16 06:20 PM
Schuth Alexander O.	COFO and Secretary	Aug 14 '23	Sale	23.67	2,772	65,613	518,989	Aug 16 06:19 PM
Watts Ryan J.	President and CEO	Aug 10 '23	Option Exercise	0.68	2,526	1,718	2,242,439	Aug 14 05:13 PM
Ho Carole	Chief Medical Officer	Aug 10 '23	Sale	24.15	2,857	68,997	185,577	Aug 14 05:12 PM
Schuth Alexander O.	COFO and Secretary	Aug 10 '23	Sale	24.18	2,853	68,986	521,761	Aug 14 05:11 PM
Watts Ryan J.	President and CEO	Aug 10 '23	Sale	25.03	2,526	63,226	2,239,913	Aug 14 05:13 PM
Schuth Alexander O.	COFO and Secretary	Jul 18 '23	Sale	30.01	9,702	291,157	518,989	Jul 19 05:10 PM
Schuth Alexander O.	COFO and Secretary	Jul 17 '23	Option Exercise	5.28	10,000	52,800	538,691	Jul 19 05:10 PM
Schuth Alexander O.	COFO and Secretary	Jul 17 '23	Sale	29.60	10,000	296,000	528,691	Jul 19 05:10 PM
SATO VICKI L	Director	Jul 17 '23	Sale	29.60	1,666	49,314	133,037	Jul 19 05:09 PM
SATO VICKI L	Director	Jun 28 '23	Sale	29.84	1,666	49,709	134,703	Jun 30 05:21 PM
Schuth Alexander O.	COFO and Secretary	May 15 '23	Option Exercise	5.28	10,000	52,800	538,691	May 17 04:56 PM
Schuth Alexander O.	COFO and Secretary	May 15 '23	Sale	28.60	10,000	286,044	528,691	May 17 04:56 PM

Open in Screener

VIR

Vir Biotechnology Inc

May 03 • 04:00PM ET

10.39

Dollar change +1.21
Percentage change 13.18	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

VIR Vir Biotechnology Inc daily Stock Chart

Held by: IJR VTI VB IWM VBK VXF IJS IWN IBB BSVO

Index	RUT	P/E	-	EPS (ttm)	-4.01	Insider Own	34.50%	Shs Outstand	134.78M	Perf Week	26.25%
Market Cap	1.41B	Forward P/E	-	EPS next Y	-3.93	Insider Trans	-0.36%	Shs Float	88.97M	Perf Month	9.71%
Income	-539.44M	PEG	-	EPS next Q	-0.91	Inst Own	53.07%	Short Float	5.79%	Perf Quarter	19.84%
Sales	79.60M	P/S	17.73	EPS this Y	23.51%	Inst Trans	-5.30%	Short Ratio	4.97	Perf Half Y	33.38%
Book/sh	11.39	P/B	0.91	EPS next Y	-11.87%	ROA	-24.19%	Short Interest	5.15M	Perf Year	-59.08%
Cash/sh	8.56	P/C	1.21	EPS next 5Y	7.00%	ROE	-30.67%	52W Range	7.61 - 27.48	Perf YTD	3.28%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-34.12%	ROI	-32.56%	52W High	-62.19%	Beta	0.46
Dividend TTM	-	Quick Ratio	9.05	Sales past 5Y	421.39%	Gross Margin	98.85%	52W Low	36.53%	ATR (14)	0.49
Dividend Ex-Date	Aug 25, 2010	Current Ratio	12.90	EPS Y/Y TTM	-273.48%	Oper. Margin	-752.67%	RSI (14)	67.80	Volatility	5.12% 4.63%
Employees	587	Debt/Eq	0.07	Sales Y/Y TTM	-82.16%	Profit Margin	-677.69%	Recom	1.78	Target Price	29.75
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	54.27%	Payout	-	Rel Volume	1.63	Prev Close	9.18
Sales Surprise	381.34%	EPS Surprise	54.35%	Sales Q/Q	-10.45%	Earnings	May 02 AMC	Avg Volume	1.04M	Price	10.39
SMA20	21.07%	SMA50	5.80%	SMA200	1.44%	Trades		Volume	1,691,223	Change	13.18%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-24	Downgrade	JP Morgan	Overweight → Neutral	$23 → $9
Sep-08-23	Downgrade	BofA Securities	Buy → Neutral	$23 → $14
Mar-06-23	Upgrade	JP Morgan	Neutral → Overweight	$35 → $34
Feb-21-23	Upgrade	Goldman	Neutral → Buy	$41 → $53
Jan-27-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$18 → $30
Sep-14-22	Initiated	SVB Leerink	Outperform	$40
Sep-09-22	Initiated	Morgan Stanley	Underweight	$15
Mar-03-22	Upgrade	Robert W. Baird	Underperform → Neutral	$36 → $28
Dec-21-21	Downgrade	Robert W. Baird	Neutral → Underperform	$36
Oct-25-21	Upgrade	JP Morgan	Underweight → Neutral	$29 → $37
Sep-22-21	Downgrade	Goldman	Buy → Neutral	$64 → $62
Jun-04-21	Resumed	Robert W. Baird	Neutral	$45
Jan-27-21	Downgrade	JP Morgan	Neutral → Underweight	$30
Jan-20-21	Reiterated	H.C. Wainwright	Buy	$100 → $125
Oct-05-20	Initiated	BofA Securities	Buy	$55
Sep-14-20	Upgrade	Goldman	Neutral → Buy	$48 → $54
Sep-11-20	Upgrade	JP Morgan	Underweight → Neutral	$29
Aug-20-20	Initiated	Needham	Buy	$62
Mar-19-20	Downgrade	JP Morgan	Neutral → Underweight	$26
Mar-13-20	Downgrade	Goldman	Buy → Neutral

Show Previous Ratings

May-03-24 01:05PM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Call Transcript (Insider Monkey) +13.18%
06:05AM	Q1 2024 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
04:06AM	Vir Biotechnology Inc (VIR) (Q1 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-02-24 09:56PM	VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024 (InvestorPlace) +5.03%
06:05PM	Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results (Business Wire)
Apr-30-24 04:05PM	Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024 (Business Wire)
Apr-24-24 12:00PM	What Makes Vir Biotechnology (VIR) a New Buy Stock (Zacks)
Apr-18-24 08:00AM	Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (Business Wire)
Apr-11-24 04:30PM	Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024 (Business Wire)
Apr-04-24 07:01PM	Vir Biotechnology Inc CEO Backer De Sells 72,995 Shares (GuruFocus.com)
Mar-22-24 07:00AM	Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results (PR Newswire)
Mar-19-24 02:58PM	From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires (InvestorPlace) -6.37%
Mar-13-24 11:07AM	Billionaires Biotech Bets: 3 Stocks Dominating Bill Gates Portfolio (InvestorPlace)
Mar-05-24 08:05AM	Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule (Business Wire)
01:54PM	Loading…
Feb-23-24 01:54PM	Q4 2023 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) +11.94%
10:34AM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:55AM	Wall Street Analysts Believe Vir Biotechnology, Inc. (VIR) Could Rally 186.41%: Here's is How to Trade (Zacks)
08:05AM	Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences (Business Wire)
Feb-22-24 05:50PM	Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-20-24 04:30PM	Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer (Business Wire)
Feb-14-24 03:45PM	3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave (InvestorPlace) +10.62%
Feb-01-24 04:05PM	Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024 (Business Wire)
Jan-15-24 11:32AM	Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why (Zacks)
Dec-17-23 07:00AM	I See a Vir-y Good Trade (TheStreet.com)
07:00AM	I See a Good Trade on a $10 Biotech Stock (TheStreet.com)
Dec-13-23 04:05PM	Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation (Business Wire) +9.11%
Dec-06-23 04:05PM	Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference (Business Wire)
Nov-30-23 06:10AM	7 Small-Cap Stocks to Buy BEFORE the Year-End Rally (InvestorPlace)
08:00AM	Loading…
Nov-13-23 08:00AM	Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLDs The Liver Meeting 2023 (Business Wire)
Nov-10-23 08:00AM	Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLDs The Liver Meeting 2023 (Business Wire) +7.99%
Nov-08-23 08:05AM	Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 (Business Wire)
Nov-04-23 11:42AM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 09:02AM	Q3 2023 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) +6.96%
Nov-02-23 07:00PM	Vir Biotechnology Inc (VIR) Reports Q3 2023 Financial Results (GuruFocus.com) +5.13%
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-30-23 08:00AM	Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer (Business Wire)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-12-23 04:05PM	Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference (GlobeNewswire) -5.98%
Oct-11-23 08:00AM	Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD's The Liver Meeting 2023 (GlobeNewswire)
Oct-05-23 04:30PM	Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023 (GlobeNewswire)
Oct-03-23 07:59AM	Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats (GlobeNewswire)
Sep-20-23 08:00AM	Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV (GlobeNewswire)
Sep-19-23 05:07AM	Down More Than 50%: 2 Strong Buy Stocks That Are Too Cheap to Ignore (TipRanks)
Sep-08-23 09:34AM	Adobe upgraded, DigitalOcean double downgraded: Wall Street's top analyst calls (The Fly)
Aug-29-23 04:30PM	Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences (GlobeNewswire)
Aug-12-23 11:05AM	10 Oversold Healthcare Stocks to Buy (Insider Monkey)
Aug-11-23 10:15AM	Is Vir Biotechnology Stock a Buy? (Motley Fool)
Aug-07-23 06:03AM	Analysts Just Made A Major Revision To Their Vir Biotechnology, Inc. (NASDAQ:VIR) Revenue Forecasts (Simply Wall St.)
Aug-04-23 01:40PM	Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 06:05PM	Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-26-23 04:05PM	Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023 (GlobeNewswire)
Jul-21-23 10:11AM	Biotech Stock Roundup: BBIO, ARGX Soar on Study Results, APLS Down on Safety Issues (Zacks) +12.99%
Jul-20-23 04:50PM	Vir's flu-prevention drug fails mid-stage clinical trial, stock dips (American City Business Journals) -44.90%
11:31AM	Why Shares of Vir Biotechnology Are Plunging Thursday (Motley Fool)
08:00AM	Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness (GlobeNewswire)
Jun-29-23 09:00AM	Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer (GlobeNewswire)
Jun-25-23 08:00AM	Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL Congress 2023 (PR Newswire)
Jun-24-23 05:30AM	Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D (GlobeNewswire)
Jun-21-23 08:00PM	VIR: Lowering target price to $26.00 (Argus Research)
Jun-07-23 02:13AM	Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL Congress 2023 (GlobeNewswire)
Jun-05-23 04:05PM	Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-17-23 04:05PM	Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders (GlobeNewswire)
May-16-23 09:25AM	Billionaire Steve Cohen Snaps Up These 2 Strong Buy Stocks Heres Why You Might Want to Ride His Coattails (TipRanks)
May-15-23 08:35AM	Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 50% of the company (Simply Wall St.)
08:00AM	Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer (GlobeNewswire)
May-11-23 08:30AM	Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFN and an NRTI (GlobeNewswire)
May-10-23 02:07PM	7 Top-Rated Stocks That Will Boost Your Portfolio in 2023 (InvestorPlace)
May-04-23 07:45PM	Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:48PM	The 7 Best Bargain Stocks to Buy for May 2023 (InvestorPlace)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-03-23 04:05PM	Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference (GlobeNewswire)
May-02-23 09:00AM	Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention (GlobeNewswire)
Apr-28-23 10:00AM	Twist Bioscience (TWST) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-27-23 10:03AM	Earnings Preview: Vir Biotechnology, Inc. (VIR) Q1 Earnings Expected to Decline (Zacks)
Apr-26-23 08:00PM	VIR: What does Argus have to say about VIR? (Argus Research)
Apr-11-23 04:05PM	Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-05-23 01:40PM	7 Thrilling Biotech Stocks for Aggressive Investors to Buy (InvestorPlace)
Mar-29-23 08:40AM	Is the Options Market Predicting a Spike in Vir Biotechnology (VIR) Stock? (Zacks)
Mar-21-23 02:33PM	Strong week for Vir Biotechnology (NASDAQ:VIR) shareholders doesn't alleviate pain of three-year loss (Simply Wall St.)
Mar-08-23 04:05PM	Vir Biotechnology to Participate in the Barclays Global Healthcare Conference (GlobeNewswire)
Mar-05-23 07:30AM	As Covid Threat Weakens, This Biotech Is Still Worth a Shot (TheStreet.com)
Mar-03-23 06:57PM	The Top 7 Growth Stocks in Biotech (InvestorPlace)
Feb-28-23 04:05PM	Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-26-23 07:13AM	Positive Sentiment Still Eludes Vir Biotechnology, Inc. (NASDAQ:VIR) Following 25% Share Price Slump (Simply Wall St.)
Feb-23-23 05:35PM	Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-22-23 08:30AM	Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UKs National Institute for Health and Care Excellence (NICE) (GlobeNewswire)
Feb-20-23 10:00AM	BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Feb-16-23 04:05PM	Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023 (GlobeNewswire)
10:01AM	Vir Biotechnology, Inc. (VIR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:30AM	Vir Biotechnology Appoints Sung Lee as Chief Financial Officer (GlobeNewswire)
Feb-14-23 04:33PM	11 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
08:19AM	Vir Biotech To Work On Next-Gen COVID-19 Solutions Independently, Or With Other Partners, As GSK Walks Out (Benzinga)
Feb-13-23 04:45PM	Vir Biotechnology Announces Amended Collaboration Agreement with GSK (GlobeNewswire)
Feb-02-23 02:19PM	The 7 Most Undervalued Biotech Stocks to Buy in February 2023 (InvestorPlace)
Jan-31-23 10:06AM	7 Healthcare Stocks That Will Be Big Winners in 2023 (InvestorPlace)
Jan-25-23 06:05PM	'You have to have the goods': Retiring Vir CEO George Scangos looks back on building great companies (American City Business Journals)

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
De Backer Marianne	Chief Executive Officer	Apr 03 '24	Sale	9.46	72,995	690,365	678,457	Apr 04 04:14 PM
HANLY ANN M.	EVP & Chief Technology Officer	Apr 01 '24	Sale	10.05	2,711	27,251	132,069	Apr 02 08:58 PM
Lee Sung	EVP & Chief Financial Officer	Mar 27 '24	Sale	9.89	6,008	59,404	100,492	Mar 28 12:18 PM
SCANGOS GEORGE A	Director	Feb 26 '24	Sale	11.65	17,722	206,522	112,989	Feb 26 07:30 PM
Pang Phillip	EVP & Chief Medical Officer	Feb 22 '24	Sale	10.05	14,568	146,344	250,111	Feb 26 07:31 PM
HANLY ANN M.	EVP & Chief Technology Officer	Feb 22 '24	Sale	10.05	12,296	123,521	134,780	Feb 26 07:34 PM
SCANGOS GEORGE A	Director	Feb 22 '24	Sale	10.05	10,028	100,737	130,711	Feb 26 07:30 PM
SCANGOS GEORGE A	Director	Feb 20 '24	Sale	10.22	16,872	172,385	140,739	Feb 20 09:02 PM
SCANGOS GEORGE A	Director	Feb 16 '24	Sale	10.24	10,878	111,386	157,611	Feb 20 09:02 PM
Pang Phillip	EVP & Chief Medical Officer	Feb 16 '24	Sale	10.24	3,321	34,006	264,679	Feb 16 06:56 PM
Pang Phillip	EVP & Chief Medical Officer	Jan 02 '24	Option Exercise	1.38	80,000	110,299	268,000	Jan 03 02:47 PM
SATO VICKI L	Director	Jun 30 '23	Sale	24.66	18,000	443,916	1,315,351	Jul 03 04:15 PM
SVF Endurance (Cayman) Ltd	10% Owner	Jun 30 '23	Sale	25.11	700	17,577	16,684,041	Jul 05 09:00 PM
SVF Endurance (Cayman) Ltd	10% Owner	Jun 29 '23	Sale	25.18	89,942	2,264,731	16,684,741	Jun 30 09:00 PM
SVF Endurance (Cayman) Ltd	10% Owner	Jun 28 '23	Sale	25.10	7,010	175,922	16,774,683	Jun 30 09:00 PM
SVF Endurance (Cayman) Ltd	10% Owner	Jun 20 '23	Sale	25.18	9,902	249,302	16,781,693	Jun 22 09:00 PM
SVF Endurance (Cayman) Ltd	10% Owner	Jun 16 '23	Sale	25.43	128,144	3,258,980	16,791,595	Jun 20 09:00 PM
SVF Endurance (Cayman) Ltd	10% Owner	Jun 15 '23	Sale	25.85	55,182	1,426,680	16,919,739	Jun 20 09:00 PM
SVF Endurance (Cayman) Ltd	10% Owner	Jun 14 '23	Sale	26.13	57,248	1,495,618	16,974,921	Jun 15 09:00 PM
SVF Endurance (Cayman) Ltd	10% Owner	Jun 13 '23	Sale	27.09	106,854	2,894,180	17,032,169	Jun 15 09:00 PM
Pang Phillip	Chief Medical Officer	Jun 07 '23	Option Exercise	1.53	5,000	7,650	193,000	Jun 08 04:30 PM
Pang Phillip	Chief Medical Officer	Jun 07 '23	Sale	25.95	5,000	129,727	188,000	Jun 08 04:30 PM
SVF Endurance (Cayman) Ltd	10% Owner	Jun 05 '23	Sale	27.32	5,197	141,998	17,139,023	Jun 06 09:00 PM
SVF Endurance (Cayman) Ltd	10% Owner	Jun 02 '23	Sale	27.32	34,365	938,732	17,144,220	Jun 06 09:00 PM
Ramasastry Saira	Director	Jun 01 '23	Sale	25.67	3,500	89,845	10,619	Jun 02 12:19 PM
Rice Steven J.	Chief Administrative Officer	Jun 01 '23	Sale	25.67	2,500	64,175	106,840	Jun 02 12:20 PM
SVF Endurance (Cayman) Ltd	10% Owner	May 24 '23	Sale	26.15	104,384	2,729,599	17,178,585	May 25 09:00 PM
SVF Endurance (Cayman) Ltd	10% Owner	May 23 '23	Sale	26.66	170,067	4,533,230	17,282,969	May 25 09:00 PM
SVF Endurance (Cayman) Ltd	10% Owner	May 22 '23	Sale	25.72	91,896	2,363,905	17,453,036	May 23 09:00 PM
SVF Endurance (Cayman) Ltd	10% Owner	May 19 '23	Sale	25.38	91,651	2,326,231	17,544,932	May 23 09:00 PM
SVF Endurance (Cayman) Ltd	10% Owner	May 05 '23	Sale	25.10	136	3,414	17,636,583	May 09 09:00 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

DNLI

Denali Therapeutics Inc

VIR

Vir Biotechnology Inc

Upgrade your FINVIZ experience